---
title: "US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment"
description: "The U.S. FDA has approved Vertex Pharmaceuticals' new triple combination treatment for cystic fibrosis, branded Alyftrek, for patients aged 6 and older. This approval enhances Vertex's position in the"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/222971088.md"
published_at: "2024-12-20T21:00:48.000Z"
---

# US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment

> The U.S. FDA has approved Vertex Pharmaceuticals' new triple combination treatment for cystic fibrosis, branded Alyftrek, for patients aged 6 and older. This approval enhances Vertex's position in the cystic fibrosis market, where it has already made significant advancements with its previous drug, Trikafta. Cystic fibrosis affects around 40,000 individuals in the U.S., leading to severe respiratory issues. The company has not yet disclosed pricing or availability details for Alyftrek.

Dec 20 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals’ (VRTX.O) next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in the market for cystic fibrosis.

The drugmaker, with almost $10 billion in sales last year, has significantly impacted cystic fibrosis treatment, transforming it from a disease with a median death age of around 30 years to a manageable condition through its drugs — such as its top-selling Trikafta.

The once-daily triple combination therapy, branded Alyftrek, was approved to treat patients aged 6 years and older.

Cystic fibrosis is an inherited disease in which the absence of a protein results in poor flow of salt and water into and out of the cells in a number of organs.

In the lungs, it causes sticky, thick mucus to build up, making it difficult to breathe and leading to progressive lung damage that can eventually result in death.

There are about 40,000 people with cystic fibrosis in the United States, according to the American Lung Association.

The company did not immediately respond to a Reuters request on pricing and availability.

### Related Stocks

- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)
- [VERX.US - Vertex](https://longbridge.com/en/quote/VERX.US.md)
- [ING.US - ING Groep](https://longbridge.com/en/quote/ING.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today | Vertex Pharmaceuticals (NASDAQ:VRTX) has delivered an average annual return of 17.22% over the past 15 years, outperform | [Link](https://longbridge.com/en/news/276269422.md) |
| Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit | Sionna Therapeutics presented its strategy for developing next-generation cystic fibrosis therapies focused on NBD1 stab | [Link](https://longbridge.com/en/news/276001201.md) |
| DELL, SPOT, UNH: The World's Biggest Hedge Fund Is Bottom Fishing the Market | Bridgewater Associates, the largest hedge fund with $136 billion in assets, made significant investments in underperform | [Link](https://longbridge.com/en/news/276384705.md) |
| Newron Pharmaceuticals startet Phase-III-Studie mit Evenamide bei therapieresistenter Schizophrenie | Newron Pharmaceuticals S.p.A. has announced the release of clinical data on Evenamide, a novel glutamate modulator being | [Link](https://longbridge.com/en/news/274605134.md) |
| Health Canada Accepts Cipher Pharmaceuticals' Natroba Submission for Review | Cipher Pharmaceuticals Inc. announced that Health Canada has accepted its new drug submission for Natroba™ (Spinosad), a | [Link](https://longbridge.com/en/news/273997136.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
